Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Carbohydr Polym ; 207: 79-90, 2019 Mar 01.
Article in English | MEDLINE | ID: mdl-30600066

ABSTRACT

Endostatin (ES) has attracted considerable attention for the treatment of anti-angiogenesis-related disorders. An 11-amino-acid peptide (ES2, IVRRADRAAVP) from the amino terminal of ES is of interest because it is the main active fragment of ES. However, both ES and ES2 have a poor stability and a short half-life, and other disadvantages need to be further resolved. Thus, we conjugated ES2 to glycol-split heparin derivatives (GSHPs) to yield the polymer-peptide conjugate, GSHP-ES2. This study showed that GSHP-ES2 exhibited increased stability, a wider pH activity range, better inhibition of endothelial cell proliferation, migration and tube formation in vitro, better anti-angiogenic activity and a longer half-life in vivo compared with ES2. These results also indicate that GSHP-ES2 has good potential for the treatment of angiogenesis-related diseases, either alone or in combination with other chemicals.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Endostatins/pharmacology , Glycopeptides/pharmacology , Heparin/chemistry , Oligopeptides/pharmacology , Angiogenesis Inhibitors/chemical synthesis , Angiogenesis Inhibitors/pharmacokinetics , Angiogenesis Inhibitors/toxicity , Animals , Cell Line , Cell Movement/drug effects , Chickens , Drug Stability , Endostatins/chemical synthesis , Endostatins/pharmacokinetics , Endostatins/toxicity , Female , Glycopeptides/chemical synthesis , Glycopeptides/pharmacokinetics , Glycopeptides/toxicity , Half-Life , Humans , Mice, Inbred BALB C , Oligopeptides/chemical synthesis , Oligopeptides/pharmacokinetics , Oligopeptides/toxicity , Zebrafish
2.
Farm. hosp ; 40(5): 352-370, sept.-oct. 2016. ilus, graf, tab
Article in English | IBECS | ID: ibc-155723

ABSTRACT

The use of parenteral antibiotic eye drop formulations with non-marketed compositions or concentrations, commonly called fortified antibiotic eye drops, is a common practice in Ophthalmology in the hospital setting. The aim of this study was to evaluate the in vitro ocular toxicity of the main fortified antibiotic eye drops prepared in the Hospital Pharmacy Departments. We have conducted an in vitro experimental study in order to test the toxicity of gentamicin, amikacin, cefazolin, ceftazidime, vancomycin, colistimethate sodium and imipenem-cilastatin eye drops; their cytotoxicity and acute tissue irritation have been evaluated. Cell-based assays were performed on human stromal keratocytes, using a cell-based impedance biosensor system [xCELLigence Real-Time System Cell Analyzer (RTCA)], and the Hen’s Egg Test for the ocular irritation tests. All the eye drops, except for vancomycin and imipenem, have shown a cytotoxic effect dependent on concentration and time; higher concentrations and longer exposure times will cause a steeper decline in the population of stromal keratocytes. Vancomycin showed a major initial cytotoxic effect, which was reverted over time; and imipenem appeared as a non-toxic compound for stromal cells. The eye drops with the highest irritating effect on the ocular surface were gentamicin and vancomycin. Those antibiotic eye drops prepared at the Hospital Pharmacy Departments included in this study were considered as compounds potentially cytotoxic for the ocular surface; this toxicity was dependent on the concentration used (AU)


El uso de reformulaciones de antibióticos parenterales en forma de colirios de composición o concentraciones no comercializadas, comúnmente denominados colirios antibióticos reforzados, es una práctica habitual en oftalmología a nivel hospitalario. El objetivo del presente trabajo ha consistido en evaluar la toxicidad ocular in vitro de los principales colirios antibióticos reforzados elaborados en los Servicios de Farmacia Hospitalaria. Hemos realizado un estudio experimental in vitro para evaluar la toxicidad de los colirios de gentamicina, amikacina, cefazolina, ceftazidima, vancomicina, colistimetato de sodio e imipenem-cilastatina en el que se ha evaluado su citotoxicidad y la irritación tisular aguda. Los ensayos celulares se realizan sobre queratocitos estromales humanos, mediante la utilización de un sistema biosensor de impedancia celular [(xCELLigence Real-Time System Cell Analyzer (RTCA)] y los ensayos de irritación ocular mediante el ensayo Hen´s Egg Test. Todos los colirios, excepto vancomicina e imipenem, han mostrado un efecto citotóxico de concentración y tiempo dependiente, siendo las concentraciones más altas y los tiempos más prolongados los que provocan un descenso más pronunciado en la población de queratocitos estromales. La vancomicina muestra un importante efecto citotóxico inicial que revierte con el transcurso del tiempo y el imipenem se muestra como un compuesto no tóxico para las células estromales. Los compuestos con mayor efecto irritante para la superficie ocular son la gentamicina y la vancomicina. Los colirios antiinfecciosos elaborados en los Servicios de Farmacia Hospitalaria estudiados se muestran como compuestos potencialmente citotóxicos para la superficie ocular, siendo esta toxicidad dependiente de la concentración utilizada (AU)


Subject(s)
Humans , Ophthalmic Solutions/toxicity , Anti-Bacterial Agents/toxicity , Pharmacy Service, Hospital/statistics & numerical data , Pharmaceutical Preparations/analysis , Cytotoxicity, Immunologic , Aminoglycosides/toxicity , beta-Lactams/toxicity , Glycopeptides/toxicity
3.
Biomacromolecules ; 17(2): 466-75, 2016 Feb 08.
Article in English | MEDLINE | ID: mdl-26691102

ABSTRACT

Nanocarriers with carbohydrates on the surface represent a very interesting class of drug-delivery vehicles because carbohydrates are involved in biomolecular recognition events in vivo. We have synthesized biocompatible miktoarm star copolymers comprising glycopolypeptide and poly(ε-caprolactone) chains using ring-opening polymerization and "click chemistry". The amphiphilic copolymers were self-assembled in water into morphologies such as nanorods, polymersomes, and micelles with carbohydrates displayed on the surface. We demonstrate that the formation of nanostructure could be tuned by chain length of the blocks and was not affected by the type of sugar residue. These nanostructures were characterized in detail using a variety of techniques such as TEM, AFM, cryogenic electron microscopy, spectrally resolved fluorescence imaging, and dye encapsulation techniques. We show that it is possible to sequester both hydrophobic as well as hydrophilic dyes within the nanostructures. Finally, we show that these noncytotoxic mannosylated rods and polymersomes were selectively and efficiently taken up by MDA-MB-231 breast cancer cells, demonstrating their potential as nanocarriers for drug delivery.


Subject(s)
Drug Carriers/chemistry , Glycopeptides/chemistry , Nanotubes/chemistry , Polyesters/chemistry , Biocompatible Materials/chemistry , Biocompatible Materials/metabolism , Biocompatible Materials/toxicity , Cell Line , Cell Survival , Click Chemistry , Drug Carriers/metabolism , Drug Carriers/toxicity , Glycopeptides/metabolism , Glycopeptides/toxicity , Humans , Hydrophobic and Hydrophilic Interactions , Nanotubes/toxicity , Polyesters/metabolism , Polyesters/toxicity , Polymerization
4.
CNS Neurol Disord Drug Targets ; 14(8): 1041-53, 2015.
Article in English | MEDLINE | ID: mdl-26295815

ABSTRACT

A dyshomeostasis of zinc ions has been reported for many psychiatric and neurodegenerative disorders including schizophrenia, attention deficit hyperactivity disorder, depression, autism, Parkinson's and Alzheimer's disease. Furthermore, alterations in zinc-levels have been associated with seizures and traumatic brain injury. Thus, altering zinclevels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. However, given the restriction of zinc uptake into the brain by the blood-brain barrier, methods for controlled regulation and manipulation of zinc concentrations within the brain are rare. Here, we performed in vivo studies investigating the possibility of brain targeted zinc delivery using zinc-loaded nanoparticles which are able to cross the blood-brain barrier. After injecting these nanoparticles, we analyzed the regional and time-dependent distribution of zinc and nanoparticles within the brain. Moreover, we evaluated whether the presence of zinc-loaded nanoparticles alters the expression of zinc sensitive genes and proteins such as metallothioneins and zinc transporters and quantified possible toxic effects. Our results show that zinc loaded g7 nanoparticles offer a promising approach as a novel non - invasive method to selectively enrich zinc in the brain within a small amount of time.


Subject(s)
Brain/drug effects , Central Nervous System Agents/administration & dosage , Drug Carriers , Nanoparticles , Zinc/administration & dosage , Animals , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Brain/metabolism , Cations, Divalent/administration & dosage , Cations, Divalent/pharmacokinetics , Cations, Divalent/toxicity , Central Nervous System Agents/pharmacokinetics , Central Nervous System Agents/toxicity , Drug Carriers/chemistry , Drug Carriers/toxicity , Drug Evaluation, Preclinical , Glycopeptides/chemistry , Glycopeptides/toxicity , Immunohistochemistry , Lactic Acid/chemistry , Lactic Acid/toxicity , Mice, Inbred BALB C , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Mitochondria/drug effects , Mitochondria/metabolism , Nanoparticles/chemistry , Nanoparticles/toxicity , Polyglycolic Acid/chemistry , Polyglycolic Acid/toxicity , Polylactic Acid-Polyglycolic Acid Copolymer , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Zinc/pharmacokinetics , Zinc/toxicity
5.
Bull Exp Biol Med ; 159(1): 53-7, 2015 May.
Article in English | MEDLINE | ID: mdl-26033590

ABSTRACT

Muramyl dipeptide ß-heptylglycoside (C7MDP) was administered to non-pregnant CBA female mice and pregnant mice after non-abortion-prone mating (CBA×BALB/c) and mating associated with a high rate of spontaneous abortion (CBA×DBA/2). In non-pregnant females, C7MDP increased the production of IL-2, IL-4, IL-5, IL-6, IL-17, IFNγ, TNFα, and GM-CSF at constant production of IL-1α and IL-10. C7MDP increased the production of IL-10 and IL-17 and suppressed the production of IFNγ on day 8 of gestation in non-abortion-prone mouse couples and stimulated the synthesis of IL-4 and IFNγ, reduced IL-5 production, and slightly increased IL-1α secretion after abortion-prone mating. On day 14 of gestation, C7MDP elevated the yield of IL-2, IL-4, IFNγ, TNFα, and GM-CSF in CBA×BALB/c and CBA×DBA/2 couples and IL-17 in the fi rst variant of mating.


Subject(s)
Adjuvants, Immunologic/toxicity , Cytokines/biosynthesis , Embryo Loss/chemically induced , Glycopeptides/toxicity , Lymphocyte Subsets/drug effects , Abortion, Spontaneous/genetics , Abortion, Spontaneous/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Cells, Cultured , Crosses, Genetic , Cytokines/genetics , Disease Models, Animal , Embryo Loss/genetics , Embryo Loss/immunology , Female , Glycopeptides/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Injections, Intraperitoneal , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interleukins/biosynthesis , Interleukins/genetics , Lymphocyte Subsets/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Mice, Inbred DBA , Pregnancy , Spleen/cytology , Spleen/immunology , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics
6.
Eur J Med Chem ; 53: 13-21, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22542107

ABSTRACT

Novel glycopeptides containing amino acids such as valine and alanine were designed, synthesized and tested for inhibition of the wild type C-SA HIV-1 protease enzyme. The incorporation of dipeptide sequences Val-Ala/Ala-Val to the sugar B-amino acid at two side chain positions resulted in a series of nine novel compounds. Compounds 3a, 3b, 3c, 3d, 4a, 4b and 5 displayed significant activities against the HIV protease enzyme. The glycopeptides are orders of magnitude less toxic to human MT-4 cells than lopinavir. Computational results were in good agreement with the experimental HIV-PR activity. The sugar hydroxyl group at the C(3) position interacts with the enzymatic Asp25/Asp25' residues. The docked position of the inhibitor is preserved during MD simulations and at least five hydrogen bond forms between the inhibitor and the enzymatic pocket. The results provide a platform for the progress of more effective carbohydrate supported inhibitors of HIV-1 and other aspartic proteases.


Subject(s)
Glycopeptides/chemical synthesis , Glycopeptides/pharmacology , HIV Protease/metabolism , HIV-1/enzymology , Models, Molecular , Protease Inhibitors/chemical synthesis , Protease Inhibitors/pharmacology , Cell Line , Chemistry Techniques, Synthetic , Esters , Glycopeptides/metabolism , Glycopeptides/toxicity , HIV Protease/chemistry , Humans , Protease Inhibitors/metabolism , Protease Inhibitors/toxicity , Protein Conformation
7.
J Immunol ; 187(10): 5429-39, 2011 Nov 15.
Article in English | MEDLINE | ID: mdl-22013111

ABSTRACT

Substance P (SP) is well known to promote inflammation in acute pancreatitis (AP) by interacting with neurokinin-1 receptor. However, mechanisms that terminate SP-mediated responses are unclear. Neutral endopeptidase (NEP) is a cell-surface enzyme that degrades SP in the extracellular fluid. In this study, we examined the expression and the role of NEP in caerulein-induced AP. Male BALB/c mice (20-25 g) subjected to 3-10 hourly injections of caerulein (50 µg/kg) exhibited reduced NEP activity and protein expression in the pancreas and lungs. Additionally, caerulein (10(-7) M) also downregulated NEP activity and mRNA expression in isolated pancreatic acinar cells. The role of NEP in AP was examined in two opposite ways: inhibition of NEP (phosphoramidon [5 mg/kg] or thiorphan [10 mg/kg]) followed by 6 hourly caerulein injections) or supplementation with exogenous NEP (10 hourly caerulein injections, treatment of recombinant mouse NEP [1 mg/kg] during second caerulein injection). Inhibition of NEP raised SP levels and exacerbated inflammatory conditions in mice. Meanwhile, the severity of AP, determined by histological examination, tissue water content, myeloperoxidase activity, and plasma amylase activity, was markedly better in mice that received exogenous NEP treatment. Our results suggest that NEP is anti-inflammatory in caerulein-induced AP. Acute inhibition of NEP contributes to increased SP levels in caerulein-induced AP, which leads to augmented inflammatory responses in the pancreas and associated lung injury.


Subject(s)
Ceruletide/toxicity , Neprilysin/physiology , Pancreatitis, Acute Necrotizing/chemically induced , Pancreatitis, Acute Necrotizing/enzymology , Acinar Cells/drug effects , Acinar Cells/enzymology , Acinar Cells/pathology , Animals , Glycopeptides/toxicity , Lung/drug effects , Lung/enzymology , Lung/pathology , Male , Mice , Mice, Inbred BALB C , Neprilysin/antagonists & inhibitors , Neprilysin/biosynthesis , Pancreatitis, Acute Necrotizing/pathology , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/biosynthesis , Random Allocation , Recombinant Proteins/administration & dosage , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/biosynthesis , Severity of Illness Index , Thiorphan/toxicity
8.
Org Lett ; 9(10): 1891-4, 2007 May 10.
Article in English | MEDLINE | ID: mdl-17432865

ABSTRACT

Evaluation of the importance of C18/C19 stereochemistry of azinomycin A/B epoxyamide partial structures with respect to DNA alkylation sequence selectivity is reported using a unique assay with a DNA oligomer containing imbedded normal (5'-GGC-3'/3'-CCG-5') and inverted (5'-CGG-3'/3'-GCC-5') azinomycin consensus cross-linking sequences. Both species were found to have unique selectivity profiles and alkylate DNA in a manner distinct from azinomycin B. Computational docking experiments support altered binding modes for the enantiomers.


Subject(s)
DNA/chemistry , Epoxy Compounds/chemical synthesis , Epoxy Compounds/toxicity , Glycopeptides/chemistry , Glycopeptides/toxicity , Naphthalenes/chemical synthesis , Naphthalenes/toxicity , Peptides/chemistry , Peptides/toxicity , Alkylation , Azabicyclo Compounds , Base Sequence , Cell Line, Tumor , Cell Survival/drug effects , Dipeptides , Epoxy Compounds/chemistry , Glycopeptides/chemical synthesis , Guanine/chemistry , Humans , Hydrogen Bonding , Intercellular Signaling Peptides and Proteins , Naphthalenes/chemistry , Nucleic Acid Conformation , Peptides/chemical synthesis , Stereoisomerism
9.
J Control Release ; 118(2): 262-70, 2007 Apr 02.
Article in English | MEDLINE | ID: mdl-17267065

ABSTRACT

To enhance gene transfection to hepatocytes by cationic liposomes, it is necessary to overcome a number of barriers existing in the process from administration to gene expression. Recently we and other group have demonstrated that the escape of plasmid DNA (pDNA)/cationic liposome complexes (lipoplexes) from the endosome to cytoplasm was rate limiting. In this study, to enhance transfection efficiency by promoting the release of lipoplexes from the endosome to cytoplasm, we proposed utilizing the "proton sponge effect". Here, we synthesized a novel pH-sensitive histidine-modified galactosylated cholesterol derivative (Gal-His-C4-Chol), for a more efficient gene delivery to hepatocytes. Liposomes containing Gal-His-C4-Chol showed much greater transfection activity than conventional Gal-C4-Chol liposomes based on a receptor-mediated mechanism in HepG2 cells. Hence, this finding should contribute to the development of gene therapy using cationic liposomes toward their clinical application.


Subject(s)
Asialoglycoprotein Receptor/metabolism , Carcinoma, Hepatocellular/metabolism , Cholesterol Esters/metabolism , DNA/metabolism , Glycopeptides/metabolism , Liposomes , Liver Neoplasms/metabolism , Transfection/methods , Active Transport, Cell Nucleus , Animals , Cations , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Survival/drug effects , Cholestenes/metabolism , Cholesterol Esters/chemistry , Cholesterol Esters/toxicity , Cytoplasm/metabolism , DNA/chemistry , Endosomes/metabolism , Genes, Reporter , Glycopeptides/chemistry , Glycopeptides/toxicity , Humans , Hydrogen-Ion Concentration , Luciferases , Mannitol/metabolism , Mice , NIH 3T3 Cells , Particle Size
10.
J Am Acad Audiol ; 14(3): 157-68; quiz 170-1, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12859140

ABSTRACT

This study describes audiologic methodology and results for evaluating potential ototoxicity in a phase I clinical trial of a new glycopeptide. This study was conducted under good clinical practices, which are regulated by the US Food and Drug Administration (FDA) (21 Code of Federal Regulations), and input from the FDA was sought prior to study implementation. Healthy, normal volunteers underwent extensive medical and audiologic assessments as part of this phase I dose- escalation study of dalbavancin, a new glycopeptide, to assess potential side effects. Audiologic monitoring included air-conduction thresholds in the conventional (0.25-8 kHz) and high-frequency (10-16 kHz) ranges. At baseline, subjects were also tested using word recognition, bone conduction testing if indicated, and tympanometry. Full testing was to be repeated if any subject met the American Speech-Language-Hearing Association (ASHA) 1994 criteria for ototoxic change. However, no subjects demonstrated ototoxic change after receiving dalbavancin, nor were any false-positive results obtained.


Subject(s)
Anti-Bacterial Agents/toxicity , Audiometry , Glycopeptides/toxicity , Hearing Loss, High-Frequency/chemically induced , Hearing/drug effects , Acoustic Impedance Tests , Adult , Analysis of Variance , Double-Blind Method , Drug Monitoring , Evoked Potentials, Auditory, Brain Stem/drug effects , Hearing Loss, High-Frequency/physiopathology , Humans , Male , Middle Aged , Reference Values , Teicoplanin/analogs & derivatives , United States , United States Food and Drug Administration , Vestibule, Labyrinth/drug effects
11.
Arzneimittelforschung ; 47(9): 1047-51, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9342421

ABSTRACT

The toxicity of Polyerga (GP-1), a mixture of low molecular weight spleen peptides, extracted from porcine spleen was examined in in vitro and in vivo experiments. The following endpoints were examined: single dose toxicity, repeated dose toxicity, reproduction toxicity, mutagenic potential, local tolerance, immunotoxicity and general pharmacology. The standard therapeutic dose is 3 x 1 ml GP-1/week. The dosage can be increased temporarily to 2 ml/d. 1 ml injection solution contains 30 micrograms oligopeptides. The LD50 was determined in rats as 3.76 ml/kg b.w. i.v. Following repeated intramuscular administration of GP-1 no toxicity appeared in rats up to a dose level of 2 ml/kg b.w./d during the 13-week treatment period. In dogs the no-effect level of GP-1 was 0.32 ml/kg b.w./d i.m. (marginal body weight reduction at 0.80 ml/kg b.w./d i.m.). In an embryotoxicity study in rats, GP-1 possessed no teratogenic properties tested at dose levels exceeding the human therapeutic dose by a factor of 1000. No mutagenic potential was observed for GP-1 in the AMES test. No local irritations were observed at the intended injection sites and at injection sites made in error. None of the in vitro and in vivo pharmacological studies revealed any effect on the parameters tested, at doses up to 500 times the clinical dose. Hence, under the present test conditions, based on a daily therapeutic dose of 1 ml GP-1/patient (approximately 0.014 ml/kg b.w./d), the therapeutic ratio is at least 50 for the most sensitive endpoint 'repeated dose toxicity' reflecting the wide margin of safety for GP-1.


Subject(s)
Antineoplastic Agents/toxicity , Glycopeptides/toxicity , Phenols/toxicity , Animals , Behavior, Animal/drug effects , Cardiovascular Diseases/chemically induced , Convulsants/toxicity , Dogs , Drug Combinations , Female , Gastrointestinal Diseases/chemically induced , Guinea Pigs , Humans , In Vitro Techniques , Mice , Mice, Inbred Strains , Mutagenicity Tests , Pain/chemically induced , Pregnancy , Rabbits , Rats , Rats, Sprague-Dawley , Rats, Wistar , Swine , Teratogens/toxicity
12.
Proc Natl Acad Sci U S A ; 91(1): 267-70, 1994 Jan 04.
Article in English | MEDLINE | ID: mdl-7506415

ABSTRACT

Bordetella pertussis releases a specific peptidoglycan fragment known as tracheal cytotoxin (TCT) that reproduces the respiratory epithelial cytopathology of whooping cough (pertussis). In vitro, TCT inhibits DNA synthesis in hamster trachea epithelial cells and causes specific destruction of ciliated cells in explants of human and hamster respiratory epithelium. We have recently demonstrated that TCT triggers production of intracellular interleukin 1 by respiratory epithelial cells, and this cytokine may act as an intermediate signal in the generation of TCT toxicity. Here we report the identification of a subsequent critical step in this pathway: induction of nitric oxide synthesis in the respiratory epithelium. The toxic effects of nitric oxide are consistent with spectroscopic evidence of the formation of iron-dinitrosyl-dithiolate complexes in TCT-treated cells. Aconitase, with its iron-sulfur center, is one expected target of nitric oxide, and TCT inhibited 80% of the activity of this enzyme in respiratory epithelial cells. The deleterious effects of TCT and interleukin 1 were dramatically attenuated by the nitric oxide synthase inhibitors NG-monomethyl-L-arginine and aminoguanidine. These results indicate that nitric oxide mediates the toxicity of TCT for the respiratory epithelium, thus implicating a central role for nitric oxide in the pathogenesis of pertussis.


Subject(s)
Nitric Oxide/toxicity , Peptidoglycan/toxicity , Trachea/drug effects , Virulence Factors, Bordetella/toxicity , Amino Acid Oxidoreductases/biosynthesis , Animals , Bordetella pertussis/pathogenicity , Cells, Cultured , Cricetinae , Enzyme Induction , Epithelium/drug effects , Glycopeptides/toxicity , In Vitro Techniques , Nitric Oxide Synthase , Trachea/cytology
13.
J Clin Invest ; 92(1): 297-302, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8325996

ABSTRACT

Components of bacterial peptidoglycans have potent biological activities, including adjuvant effects, cytotoxicity, and induction of sleep. Mixtures of peptidoglycan components also induce inflammation in the lung, subarachnoid space, and joint, but the structural requirements for activity are unknown. Using a rabbit model for meningitis, we determined the biological activities of 14 individual muramyl peptides constituting > 90% of the peptidoglycan of the gram-negative pediatric pathogen Haemophilus influenzae. Upon intracisternal inoculation, most of the muropeptides induced leukocytosis in cerebrospinal fluid (CSF), influx of protein into CSF, or brain edema, alone or in combination. The disaccharide-tetrapeptide, the major component of all gram-negative peptidoglycans, induced CSF leukocytosis and protein influx at doses as low as 0.4 microgram (0.42 nM). Modification of the N-acetyl muramic acid or substitution of the alanine at position four in the peptide side chain decreased leukocytosis but enhanced brain edema. As the size of the muropeptide increased, the inflammatory activity decreased. Muropeptide carrying the diaminopimelyl-diaminopimelic acid cross-link specifically induced cytotoxic brain edema. These findings significantly expand the spectrum of biological activities of natural muramyl peptides and provide the basis for a structure-activity relationship for the inflammatory properties of bacterial muropeptides.


Subject(s)
Glycopeptides/toxicity , Haemophilus influenzae/pathogenicity , Meningitis/microbiology , Peptidoglycan/toxicity , Amino Acid Sequence , Animals , Blood-Brain Barrier , Brain Edema/chemically induced , Chemotaxis, Leukocyte , Haemophilus influenzae/chemistry , Molecular Sequence Data , Rabbits , Structure-Activity Relationship
14.
Eksp Klin Farmakol ; 55(1): 38-40, 1992.
Article in Russian | MEDLINE | ID: mdl-1305431

ABSTRACT

It has been established that a non-dialyzed fraction of ammoniacal extract from P. molissima contains an anticoagulant-glycopeptide. In in vivo experiments, it produces stable hypocoagulemia, primarily blocking fibrin self-assemblage, and prevents the animal's death from thromboplastinemia. It has been found that the aforesaid action does not exert any adverse effect on the blood contents, arterial pressure, respiration or urinary renal function.


Subject(s)
Anticoagulants/pharmacology , Glycopeptides/pharmacology , Plant Extracts/pharmacology , Animals , Anticoagulants/isolation & purification , Anticoagulants/toxicity , Blood Coagulation/drug effects , Blood Pressure/drug effects , Dialysis , Dose-Response Relationship, Drug , Fibrin/drug effects , Glycopeptides/isolation & purification , Glycopeptides/toxicity , Plant Extracts/isolation & purification , Plant Extracts/toxicity , Rabbits , Rats , Respiration/drug effects , Time Factors
15.
Article in Russian | MEDLINE | ID: mdl-1858472

ABSTRACT

The action of peptidoglycans (PG) of different origin has been experimentally studied in vivo. In these experiments PG of bacterial origin, such as blastolysin (BL), and synthetic PG, viz. muramyldipeptide (MDP) and its analog glucosaminylmuramyldipeptide (GMDP) have been used. Their toxicity, allergenic action, their effect on the phagocytic activity of peritoneal exudate macrophages (PEM), the accumulation of antibody-producing cells in the spleen, antibody titer in the blood serum and delayed hypersensitivity to nonbacterial antigens have been determined. As revealed in this study, BL does not differ from MDP in its toxicity and allergenic action. The phagocytic activity of PEM under the influence of BL only insignificantly differs from their activity under the influence of MDP, but is lower than under the influence of GMDP. The adjuvant action of BL is somewhat higher than that of synthetic PG.


Subject(s)
Anti-Bacterial Agents , Immunity/drug effects , Lactobacillus , Peptidoglycan/pharmacology , Acetylmuramyl-Alanyl-Isoglutamine/analogs & derivatives , Acetylmuramyl-Alanyl-Isoglutamine/immunology , Acetylmuramyl-Alanyl-Isoglutamine/pharmacology , Acetylmuramyl-Alanyl-Isoglutamine/toxicity , Adjuvants, Immunologic/pharmacology , Adjuvants, Immunologic/toxicity , Animals , Dose-Response Relationship, Immunologic , Female , Glycopeptides/immunology , Glycopeptides/pharmacology , Glycopeptides/toxicity , Guinea Pigs , Hypersensitivity, Delayed/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Peptidoglycan/immunology , Peptidoglycan/toxicity , Phagocytosis/drug effects , Phagocytosis/immunology , Time Factors
16.
Br J Haematol ; 76 Suppl 2: 30-4, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2149049

ABSTRACT

Infections due to Gram-positive bacteria, especially coagulase-negative staphylococci, have been increasing in immunocompromised patients during the last 5 years because of an increased use of Hickman catheters and oral gut decontamination with quinolones. Teicoplanin, a new glycopeptide antibiotic, has a long plasma half-life which allows once-a-day bolus administration, making it a 'user friendly' agent. A randomized comparative evaluation of teicoplanin plus aztreonam versus gentamicin plus piperacillin in leukaemic patients with a clinical diagnosis of septicaemia was undertaken. The objectives of this study were (1) to evaluate the efficacy and safety of teicoplanin and aztreonam in comparison to a 'standard antibiotic' regimen and (2) to assess the local and systemic tolerance of these drugs. Results of the study in more than 70 patients to date are presented, and the role of anti-Gram-positive antibiotics in the management of severe sepsis in immunocompromised patients is discussed.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Sepsis/drug therapy , Adult , Aztreonam/therapeutic use , Aztreonam/toxicity , Bacteria/isolation & purification , Drug Therapy, Combination , Female , Gentamicins/therapeutic use , Glycopeptides/therapeutic use , Glycopeptides/toxicity , Humans , Leukemia/complications , Male , Middle Aged , Neoplasms/complications , Piperacillin/therapeutic use , Prospective Studies , Sepsis/microbiology , Teicoplanin
17.
Antibiot Khimioter ; 35(11): 21-4, 1990 Nov.
Article in Russian | MEDLINE | ID: mdl-2092632

ABSTRACT

Chemotherapeutic efficacy of eremomycin in combination with tobramycin was investigated on a model of experimental sepsis of albino mice caused by Staphylococcus aureus cultures resistant to methicillin. Eremomycin is a novel original antibiotic of the glycopeptide structure isolated in the USSR and tobramycin is an aminoglycoside. Acute toxicity of the combination with a wide range of the dose fixed proportions was studied on mice and the nephrotoxic action of the antibiotics and their combinations administered intravenously for 5 days was studied on albino rats. The experiments showed that the chemotherapeutic effect of eremomycin in combination with tobramycin was of synergistic nature. Acute toxicity of the combined drugs mainly summed up and somewhat increased when the proportion of tobramycin and eremomycin was 1:2.4 or 1:3.6. Eremomycin had a dose-depended nephrotoxicity. Summing up of the nephrotoxic action of the drugs on their combined use was observed.


Subject(s)
Anti-Bacterial Agents , Kidney Diseases/chemically induced , Staphylococcal Infections/drug therapy , Tobramycin/therapeutic use , Animals , Drug Synergism , Drug Therapy, Combination/therapeutic use , Drug Therapy, Combination/toxicity , Glycopeptides/therapeutic use , Glycopeptides/toxicity , Mice , Rats , Tobramycin/toxicity
18.
Antibiot Khimioter ; 33(4): 280-6, 1988 Apr.
Article in Russian | MEDLINE | ID: mdl-3389957

ABSTRACT

Toxicity of eremomycin was studied after its multiple parenteral administration to albino rats, guinea pigs and dogs in doses equivalent by the body surface to the daily doses for humans i. e. 1 and 3 g. The antibiotic was administered for 1 to 6 months. Tolerance of the antibiotic by the dogs after intravenous and intramuscular administration was satisfactory. In some animals there were observed an insignificant increase in the activity of alanine aminotransferase and a rise in the level of urea in blood serum. Pathomorphological examination of the internal organs of the albino rats and dogs showed that in high doses the antibiotic could have a damaging effect on the kidneys and epithelium of the gastrointestinal tract. The level of the damages depended on the dose of the antibiotic and duration of its use. The damages induced by eremomycin were reversible. It had no marked effect on the peripheral blood count, coagulation system and erythrocyte resistance. In the tested doses the antibiotic had no unfavourable effect on the hearing function in the experiments with guinea pigs. Studies with rats revealed that eremomycin had no teratogenic effect. A slightly pronounced embryotoxic action was observed only after using the antibiotic in doses exceeding more than 12 times the approximate therapeutic dose.


Subject(s)
Anti-Bacterial Agents/toxicity , Embryonic and Fetal Development/drug effects , Animals , Auditory Perception/drug effects , Dogs , Drug Evaluation, Preclinical , Female , Glycopeptides/toxicity , Guinea Pigs , Intestine, Small/drug effects , Intestine, Small/pathology , Kidney/drug effects , Kidney/pathology , Liver/drug effects , Liver/pathology , Male , Rats , Stomach/drug effects , Stomach/pathology
19.
Ophthalmic Surg ; 19(2): 119-23, 1988 Feb.
Article in English | MEDLINE | ID: mdl-2964586

ABSTRACT

We investigated the intraocular penetration and retinal toxicity of teicoplanin, a relatively new glycopeptide antibiotic with activity similar to vancomycin when used to inhibit staphylococci and other gram positive organisms, particularly Streptococcus faecalia. Topically administered teicoplanin penetrated poorly into the aqueous and vitreous in rabbit eyes. Subconjunctival injection of the drug yielded aqueous levels above the minimum inhibiting concentration (3.1 micrograms/ml) only at one hour after injection. In the vitreous, drug levels were above the mean inhibitory concentration at 30 minutes after the subconjunctival injection, but rapidly declined thereafter. The maximum nontoxic, single-dose, intravitreal injection was 750 micrograms/0.1 ml. Rabbits received 8 micrograms/ml of teicoplanin in an intravitreal infusion solution without demonstrable retinal toxicity.


Subject(s)
Eye/metabolism , Retina/drug effects , Animals , Conjunctiva , Electroretinography , Glycopeptides/toxicity , Injections , Lens, Crystalline/surgery , Ophthalmic Solutions , Rabbits , Retina/physiopathology , Teicoplanin , Vitrectomy , Vitreous Body
20.
Antibiot Med Biotekhnol ; 32(12): 910-5, 1987 Dec.
Article in Russian | MEDLINE | ID: mdl-2830839

ABSTRACT

Eremomycin is relatively low toxic. LD50 of eremomycin on its intravenous administration to albino mice amounted to 1760 (1460-2130) mg/kg. It is 2.6, 3.5 and 6 times less toxic than ristomycin, vancomycin and teicoplanin, respectively. The rate of intravenous administration had no significant effect on eremomycin toxicity. Sensitivity of adult and preadolescent mice to eremomycin was almost the same. Eremomycin toxicity for male mice was somewhat higher than that for female mice. The use of 5 per cent glucose solution instead of distilled water as a solvent lowered 1.3-fold the toxicity of eremomycin in albino mice when it was administered intravenously. The toxic effect of eremomycin on the renal function played a significant role in the mechanism of the animal death due to the antibiotic. In experiments with guinea pigs eremomycin showed no allergenic effect. Unlike the other representatives of glycopeptide antibiotics, eremomycin had practically no local irritating effect which provided its recommendation for clinical trials not only as an intravenous but also intramuscular antibiotic.


Subject(s)
Anti-Bacterial Agents/toxicity , Animals , Cats , Dogs , Dose-Response Relationship, Drug , Glycopeptides/administration & dosage , Glycopeptides/pharmacokinetics , Glycopeptides/toxicity , Guinea Pigs , Lethal Dose 50 , Mice , Rats , Ristocetin/toxicity , Teicoplanin , Vancomycin/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...